The World Health Organization will decide later this month or in May on the emergency use listings for Sinopharm’s (1099.HK) and Sinovac (SVA.O) COVID-19 vaccines after an extensive review, said a WHO European region on Thursday.
“We are in contact with them to review the dossiers that were sent by both vaccine manufacturers,” said WHO-Europe vaccination specialist Siddhartha Datta at a virtual news conference. “We will hear about a decision on the emergency use list in April or early May, so keep an eye on that.”
A WHO panel in the final stages of reviewing Chinese vaccines said that the decision of at least one could come on April 26, while a second meeting is planned for May 3, if more time is needed to make a decision on the two. vaccines.
This WHO emergency list is a prerequisite for purchasing the COVAX vaccine sharing facility, designed to provide vaccines to the poorest countries. It also helps to guide countries with less developed regulatory systems on the safety and efficacy of a vaccine.
So far, WHO has published emergency lists for the COVID-19 vaccine from Pfizer and BioNTech (22UAy.DE), as well as versions of the AstraZeneca vaccine (AZN.L) made by the Serum Institute in India and AstraZeneca-SKBio in Korea. southern.
The CanSino vaccine relies on a viral vector to deliver DNA to induce an immune response, a technique similar to that used in AstraZeneca and Johnson & Johnson (JNJ.N) vaccines now being investigated for their association with very rare blood clots combined with low platelet counts.
CanSino said there were no reports of blood clots. Read More
The Sinovac vaccine, being used in places like Hong Kong and Brazil, depends on inactivated coronaviruses to generate an immune response, a technique used for decades, including against polio. Read More
Our Standards: Thomson Reuters Trust Principles.